Biotech
BeOne Medicines redomiciles to the Basel Area
Location
Basel-Stadt
Industry
Biopharma
Employees
10,000+
Solving the scale challenge: a European base where science meets execution
As BeOne Medicines advanced a diversified oncology portfolio for patients worldwide, it needed a European base that could power both science and commercialization. It wasn’t about an address; it was about the daily mechanics of building medicines—hiring rare R&D and commercial talent, stepping across the street to meet partners and operating in a predictable environment so teams spend their time on patients, not paperwork.
Why the Basel Area was the right move
The global biopharma company BeOne Medicines (formerly BeiGene) recently entered a new chapter: redomiciled to Switzerland and anchored with its global headquarters in Basel, one of the world’s most thriving life sciences hubs. This move reflects a clear strategy: combine world-class oncology science with an ecosystem that concentrates talent, partners and predictable business framework conditions in one place.
Basel Area’s cross-border supercluster concentrates life sciences like few places on earth. Within one compact city you find Switzerland’s largest pool of life sciences talent and a dense web of global pharma, biotechs, institutes and service providers—often just a tram ride apart. With Switzerland’s stability and predictable framework conditions, plans move from slide deck to execution with fewer surprises.
With its European operations anchored in the Basel Area, Roivant is better positioned than ever to deliver transformative medicines to patients — faster, smarter, and at scale.
Our experience in setting up in Basel was similar to the city’s riverside current – effortless, smooth and refreshing. The support offered at launch let us focus on our operations with confidence.
Co-Founder, Chairman and CEO of BeOne Medicines
The Basel Area also offered the credibility and connectivity BeOne Medicines wanted: neighbors who set the pace in oncology and immunology, and fast links to major markets. For a global oncology company, that combination turns a headquarters decision into a growth decision.
A confident HQ decision and a platform for growth
On 27 May 2025, the company completed its redomiciliation to Switzerland and launched its new name – BeOne Medicines – confirming Basel as its global headquarters. The move underscored BeOne Medicines’ ambition to accelerate access to innovative cancer medicines through a hub that brings together talent density, partnering opportunities and reliable operating conditions.
Day to day, the Basel Area shortens the distance between critical steps. Partner introductions happen faster. Clinical and data collaborations cross borders without friction. Experienced commercial leaders are already here. The result is a headquarters that accelerates rather than distracts.
This move not only strengthens our operational presence in one of the world’s most dynamic biotech hubs, where more than 30,000 life sciences professionals work and live, but also enables closer collaboration with key scientific, regulatory and policy stakeholders across Europe.
Head of Region Europe, BeOne Medicines
People, culture and momentum
For leaders building global oncology companies, place matters. In Basel, teams recruit specialized talent quickly, collaborate with world-class neighbors and live in a city that blends Swiss reliability with European culture. That mix makes relocation and retention easier, and it sustains momentum over the long run.
The biopharma industry is all about innovation, and innovation needs talented people. That’s why we decided to set up our European headquarters in Basel.
President and COO, BeOne Medicines
